RecruitingNCT05590637
Pimavanserin or quetiapine for hallucinations or delusions in Lewy body disease
About this title
Read the official source — NCT05590637Medication studyUnited StatesSchizophrenia
Understand this study
- Listed locations
- San Antonio and 1 more locationSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 22, 2022
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 94
- Sponsor
- The University of Texas Health Science Center at San Antonio
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- Not clearly listed
- Official registry ID
- NCT05590637
- Official title
Show the full official title
A Pragmatic Randomized Trial Comparing Antipsychotics in Lewy Body Disease
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
San Antonio
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is The University of Texas Health Science Center at San Antonio, a university.
Does this study involve medication?
Yes. The study involves medication, including Pimavanserin and Quetiapine.
Is this study still recruiting?
The registry lists this study as recruiting.
